Cargando…

High-throughput profiling identifies clinically actionable mutations in salivary duct carcinoma

BACKGROUND: Salivary duct carcinoma (SDC) is a highly aggressive subtype of salivary gland cancers and there is no established standard therapy for this disease. Thus, development of molecular markers for SDC will be important to guide the diagnosis and therapy of this aggressive tumor. METHODS: We...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ku, Bo Mi, Jung, Hyun Ae, Sun, Jong-Mu, Ko, Young Hyeh, Jeong, Han-Sin, Son, Young-Ik, Baek, Chung-Hwan, Park, Keunchil, Ahn, Myung-Ju
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4216375/ https://www.ncbi.nlm.nih.gov/pubmed/25343854 http://dx.doi.org/10.1186/s12967-014-0299-6

Ejemplares similares

Integrative genomic analysis of salivary duct carcinoma
por: Kim, Youngwook, et al.
Publicado: (2020)

Treatment outcomes in metastatic and localized high-grade salivary gland cancer: high chance of cure with surgery and post-operative radiation in T1–2 N0 high-grade salivary gland cancer
por: Jang, Jeon Yeob, et al.
Publicado: (2018)

Association Between PD-L1 and HPV Status and the Prognostic Value of PD-L1 in Oropharyngeal Squamous Cell Carcinoma
por: Kim, Hae Su, et al.
Publicado: (2016)

An increase of CD8(+) T cell infiltration following recurrence is a good prognosticator in HNSCC
por: So, Yoon Kyoung, et al.
Publicado: (2020)

Induction chemotherapy followed by concurrent chemoradiotherapy versus CCRT for locally advanced hypopharynx and base of tongue cancer
por: Lim, Sung Hee, et al.
Publicado: (2021)

Genetic Alterations and Their Clinical Implications in High-Recurrence Risk Papillary Thyroid Cancer
por: Lee, Min-Young, et al.
Publicado: (2017)

Treatment Results of Major Salivary Gland Cancer by Surgery with or without Postoperative Radiation Therapy
por: Noh, Jae Myoung, et al.
Publicado: (2010)

Prognostic Value of Volume-Based Positron Emission Tomography/Computed Tomography in Patients With Nasopharyngeal Carcinoma Treated With Concurrent Chemoradiotherapy
por: Moon, Seung Hwan, et al.
Publicado: (2015)

The Prognostic Role of p16 Expression in Tonsil Cancer Treated by Either Surgery or Radiation
por: Kim, Tae Wook, et al.
Publicado: (2012)

EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation
por: Park, Sehhoon, et al.
Publicado: (2020)

Sentinel Lymph Node Radiolocalization with (99m)Tc Filtered Tin Colloid in Clinically Node-Negative Squamous Cell Carcinomas of the Oral Cavity
por: Jeong, Han-Sin, et al.
Publicado: (2006)

Adenocarcinoma of the minor salivary gland with concurrent MAML2 and EWSR1 alterations
por: Choi, Sangjoon, et al.
Publicado: (2021)

Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer
por: Ku, Bo Mi, et al.
Publicado: (2019)

The Clinical Usefulness of (18)F-FDG PET/CT for the Evaluation of Lymph Node Metastasis in Periorbital Malignancies
por: Baek, Chung-Hwan, et al.
Publicado: (2009)

The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer
por: Jung, Hyun Ae, et al.
Publicado: (2020)

Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model
por: Ku, Bo Mi, et al.
Publicado: (2018)

Tumor infiltrated immune cell types support distinct immune checkpoint inhibitor outcomes in patients with advanced non‐small cell lung cancer
por: Ku, Bo Mi, et al.
Publicado: (2021)

Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment
por: Kim, Kyung Hwan, et al.
Publicado: (2020)

Immunological Characteristics of Hyperprogressive Disease in Patients with Non-small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 Abs
por: Kim, Kyung Hwan, et al.
Publicado: (2020)

Spontaneous regression of metastatic cancer cells in the lymph node: a case report
por: Choi, Nayeon, et al.
Publicado: (2014)

Regulatory (FoxP3(+)) T cells and TGF-β predict the response to anti-PD-1 immunotherapy in patients with non-small cell lung cancer
por: Koh, Jiae, et al.
Publicado: (2020)

The Effectiveness of Maintenance Pharmacotherapies for Non-Small Cell Lung Cancer
por: Ahn, Myung-Ju, et al.
Publicado: (2012)

Control of Na+ channels in salivary duct cells.
por: Dinudom, A, et al.
Publicado: (2000)

Salivary Duct Cancer Metastasis Mimicking Primary Breast Cancer: A Case Report and Review
por: Alzuhair, Aisha M., et al.
Publicado: (2019)

CD4+CD56+CD68+hematopoietic tumor of probable plasmacytoid monocyte derivation with weak expression of cytoplasmic CD3.
por: Ko, Young Hyeh, et al.
Publicado: (2002)

Mutational status of TP53 defines the efficacy of Wee1 inhibitor AZD1775 in KRAS-mutant non-small cell lung cancer
por: Ku, Bo Mi, et al.
Publicado: (2017)

ERK inhibitor ASN007 effectively overcomes acquired resistance to EGFR inhibitor in non‐small cell lung cancer
por: Ku, Bo Mi, et al.
Publicado: (2022)

Longitudinal monitoring by next‐generation sequencing of plasma cell‐free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors
por: Kwon, Minsuk, et al.
Publicado: (2022)

Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: Are They Different from Those with Common EGFR Mutations?
por: Jung, Hyun Ae, et al.
Publicado: (2020)

Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in Korea
por: Lee, Kangkook, et al.
Publicado: (2020)

Comprehensive evaluation of the clinical utility of plasma EGFR test in non-small cell lung cancer patients with acquired resistance to first-line EGFR inhibitors
por: Kim, Hongsik, et al.
Publicado: (2021)

Predictive and Prognostic Value of (18)F-fluorodeoxyglucose Uptake Combined with Thymidylate Synthase Expression in Patients with Advanced Non-Small Cell Lung Cancer
por: Moon, Seung Hwan, et al.
Publicado: (2019)

Affections of the salivary ducts in buffaloes
por: Misk, N.A., et al.
Publicado: (2014)

The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma
por: Ku, Bo Mi, et al.
Publicado: (2016)

Prognostic and Predictive Value of KRAS Mutations in Advanced Non-Small Cell Lung Cancer
por: Sun, Jong-Mu, et al.
Publicado: (2013)

Long-term Survival in Non–Small Cell Lung Cancer Patients with Metachronous Brain-Only Oligorecurrence Who Underwent Definitive Treatment
por: Kim, Hongsik, et al.
Publicado: (2022)

Expanded Access Program Pralsetinib in Advanced Non–Small Cell Lung Cancer with Rearranged during Transfection (RET) Gene Rearrangement
por: Jeon, Youngkyung, et al.
Publicado: (2023)

A Case of Cutaneous Metastases of Salivary Duct Carcinoma Mimicking Radiation Recall Dermatitis
por: Shin, Jee Yon, et al.
Publicado: (2020)

Ectopic Thyroid Nodule in Thyroglossal Duct
por: Shin, Ah-Young, et al.
Publicado: (2011)

PD‐1 inhibitors for non‐small cell lung cancer patients with special issues: Real‐world evidence
por: Byeon, Seonggyu, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7pr3ij9ic15pntln9pr856rs7r